Company Overview
Overcoming science’s hardest obstacles is our highest priority.
Rallybio is a clinical-stage biotechnology company built around a team of seasoned industry leaders.
Frustrated by the fact that so many devastating diseases still lack adequate treatments, we’ve made it our mission to discover, develop, manufacture, and deliver therapies that meaningfully improve the lives of patients with severe and rare diseases.
Our success depends on rallying the best people, partners, and science. It hinges on fearlessly creating paths forward that no one has attempted before. And of course, it means striving to develop and deliver the truly transformational.
Following the science wherever it goes.
Co-Founder and Executive Chairman
Working in parallel paths to make unparalleled progress.
Our experienced drug development executives have been integral to the approvals of more than 30 drugs at leading global pharmaceutical and biotech companies.
Leveraging our team’s expertise, we continue to expand our diversified portfolio of product candidates in order to significantly improve the lives of patients suffering from devastating and rare diseases.
Taking the paths of most resistance.
Our Team
Driving product candidates through clinical development to regulatory approvals isn’t easy, but we know it’s possible.
Over the course of their careers, members of our team have played critical roles in developing and implementing novel clinical trial designs and have successfully conducted clinical trials in never-before-treated patient populations. Our unique collective experience positions us to efficiently and expertly execute at each step in the research and development process, significantly enhancing the value we can bring to product candidates and to patients.
Rachael has close to 20 years of biopharmaceutical industry experience in all aspects of technical operations. Prior to joining Rallybio, she served as Vice President of Global Process Development at Alexion Pharmaceuticals, where she led biologic and small molecule process development, analytical and formulation development, tech transfer, and life cycle management.
Rachael earned both her B.S. in chemistry and Ph.D. in biophysical chemistry from Imperial College London and was a postdoctoral research associate at Yale University.
OTHER THINGS WORTH KNOWING ABOUT ME:
I don’t like it when it rains on the weekend.
My favorite charity is the Women’s Refugee Commission.
I grew up in a sleepy village in the English countryside
Róisín has over 25 years of biopharmaceutical industry experience, specifically in advancing products through the development continuum to commercialization. Most recently, she served as Vice President and Global Medicine Team Leader at Alexion Pharmaceuticals, where she led teams in the development and registration of new treatments for rare and ultra-rare neurology indications. In 2019, Róisín was the recipient of an HBA Luminary Award from the Healthcare Businesswomen’s Association. Prior to Alexion, Róisín worked with Pfizer in the UK and the US in various roles of increasing responsibility, including early- and late-stage development portfolio operations and global clinical leadership roles in different therapeutic areas.
Róisín earned a B.S. in pharmacy from De Monfort University in Leicester, UK, and a Ph.D. in neuropharmacology from the University of Wales, College of Cardiff.
OTHER THINGS WORTH KNOWING ABOUT ME:
My dream vacation is hiking in Patagonia.
When I’m not working, I’m likely golfing (regardless of season) or otherwise outdoors.
I grew up in the north of Ireland – Belfast and Portstewart.
Sharon has over 20 years of experience in the biopharmaceutical industry, leading the way in the development and validation of immunoassays. Most recently, she served as Director, Bioanalytical Development, R&D at Alexion AstraZeneca Rare Disease supervising a team of scientists and leading the development and validation of immunoassays to support nonclinical and clinical studies using a variety of platforms in multiple therapeutic modalities. Prior to Alexion, Sharon worked at Pfizer as a principal scientist in the GLP Bioanalytical Group and managed the critical reagent group and was also a clinical study recruitment manager on early-stage studies.
Sharon earned a B.Sc. (Hons) in Biochemistry from Glasgow College of Technology, and a Ph.D. in Biochemistry from the University of Manchester, UK.
OTHER THINGS WORTH KNOWING ABOUT ME:
- My dream vacation: Anywhere that is sunny and has white sandy beaches
- Last concert I attended: PINK
- Favorite sports teams: New York Yankees and Manchester City
Michael brings over 30 years of clinical operations experience to Rallybio. He spent over 20 years at Alexion Pharmaceuticals in clinical operations, most recently serving as Executive Director of Clinical Business Operations, where he oversaw the strategic planning of clinical, scientific and operational aspects of numerous clinical trials. Prior to Alexion, Mike spent 10 years in pharmaceutical sciences at Bayer and four years at Genentech, conducting bench research in immunology and metabolic and rheumatic disorders.
Mike received a B.S. in microbiology from the University of Maine.
OTHER THINGS WORTH KNOWING ABOUT ME:
My favorite city to visit is Lima, Peru.
My favorite charity is Music Haven.
When I’m not working, I am at home listening to music and enjoying a gourmet meal prepared by Alejandro.
Derek has more than 25 years of biopharmaceutical commercial experience in both strategic and operational capacities. Prior to joining Rallybio, Derek served as the Vice President of Global Marketing and Commercial Operations at Chiasma Pharma, where he built a team responsible for launching the company’s first product for a rare disease. Prior to this, Derek led a global team at Alexion Pharmaceuticals to prepare for the commercialization of Ultomiris® and for the marketing of Soliris® in two ultra-rare hematology diseases. Derek previously worked for 12 years at Boehringer Ingelheim in the U.S. and Germany holding leadership roles of increasing responsibility spanning product launches, new product planning, and market access. He began his career as a management consultant at Accenture.
Derek received an MBA from The Tuck School of Business at Dartmouth College and a bachelor’s degree in cellular structure and function and in economics from Middlebury College.
OTHER THINGS WORTH KNOWING ABOUT ME:
When I’m not working, I am spending time with my wife and two boys, ideally outside.
My favorite animal is my canine hiking companion, Bromley.
I grew up on Long Island, NY and spent summers in Southern VT.
Danielle has more than 6 years of experience working in the human resources (HR) biopharmaceutical space. She joins Rallybio from Alexion, AstraZeneca Rare Disease, where she held roles of increasing responsibility and most recently served as the People & Culture Partner for the company’s research and development (R&D) organization. During her time in the role, Danielle supported leaders in building strategic and dynamic teams while fostering company culture and employee experience. Danielle worked at Alexion prior to its merger with AstraZeneca. In that time, she focused on operations and systems and supporting HR service delivery for over 2,500 global employees.
Danielle earned her bachelor’s degree and MBA in human resource management from Albertus Magnus College and her master’s degree in corporate compliance from Fordham University School of Law.
OTHER THINGS WORTH KNOWING ABOUT ME:
My dream vacation is to go to Dubai (… I just need to get over my fear of long flights first).
I cannot live without my morning routine of an early workout, journaling and coffee before the sun rises.
My favorite charity is Rescue Dogs Rock NYC. I am an animal advocate and have three rescue dogs of my own!
Zhiliang is a seasoned research and development (R&D) leader with over 15 years of experience in driving innovation and helping patients with unmet medical needs. Prior to joining Rallybio, Zhiliang worked at Inozyme Pharma where he served as Vice President of Research Science. Additionally, Zhiliang has worked at Regeneron and Alexion and has extensive experience leading various R&D teams.
He has led research teams working on innovative therapies to treat cardiovascular, metabolic and musculoskeletal diseases. He has also contributed immensely to advancing development of both ERT and mRNA therapeutics for rare diseases.
Zhiliang earned his bachelor’s degree in Biological Sciences from the University of Science and Technology of China. He then went on to earn his Ph.D. in Biochemistry and Molecular Pharmacology from the University of Massachusetts Medical School and completed his postdoctoral training at University of California, Berkeley as an HHMI research specialist.
OTHER THINGS WORTH KNOWING ABOUT ME:
I cannot live without a fresh cup of tea every day.
My favorite sports team is the 1990s Chicago Bulls.
I grew up in a small city by the Yangzi River known for its beauty, history, and as the last home of Li Bai, one of ancient China’s greatest poets.
Vertrice has more than 10 years of clinical trial experience, both in-house and within CROs. Prior to joining Rallybio, Vertrice was Associate Director, Clinical Operations at Lundbeck Pharmaceuticals where she led the development of clinical study plans, oversight and adherence, timelines, deliverables and document reviews. Vertrice has held various roles managing clinical trial development and projects at such companies as ICON Clinical Research, Ortho Clinical Diagnostics, Daiichi Sankyo, inVentiv Health Clinical and Quintiles.
Vertrice earned a B.S. in Clinical Research from the University of North Carolina at Wilmington and a B.S. in Nursing from North Carolina Central University. And she has held a Good Clinical Practice (GCP) certification since 2013.
OTHER THINGS WORTH KNOWING ABOUT ME:
When I’m not working, I’m…:Moming! A mom’s day is never over.
I cannot live without: My family/friends, love, spirituality, goals/dreams, and a hair appointment!
My greatest non-work accomplishment: Individual’s lives I have positively impacted over my lifetime. If I can save a person from a burden or mistake or help during a troubling time, it is my duty to do so.
Laura has more than 14 years of experience in the biotech industry. Her broad background includes experience in global pricing and reimbursement, corporate operations, and investor relations at Alexion Pharmaceuticals. Prior to Alexion, Laura was a Consultant at Insight Strategy Advisors, a healthcare strategy consulting firm, where she focused on patient access, pricing, and supply chain strategies. Before this, she held positions of increasing responsibility at Canaccord Genuity Group, including Vice President of Biotech Equity Research.
She earned a B.A. in behavioral biology from Johns Hopkins University and a Ph.D. in pharmacology and signal transduction from the New York University School of Medicine.
OTHER THINGS WORTH KNOWING ABOUT ME:
My favorite city to visit is Rome.
My favorite charity is the Michael Mosier Defeat DIPG Foundation.
I grew up in Virginia, but I’m a New Yorker at heart.
Mike has more than 20 years of legal and business experience, including in private practice and as a member of life science leadership and executive management teams. Prior to joining Rallybio, Mike served as General Counsel and Secretary for SpringWorks Therapeutics, where he helped facilitate the successful implementation of the company’s IPO among other milestones and accomplishments. Previously, he held leadership roles at Alexion Pharmaceuticals, where he assumed positions of increasing responsibility in the company’s legal department and oversaw corporate governance initiatives, public reporting, and securities compliance and corporate transactions. He was also responsible for managing the legal department’s corporate, R&D, business development and employment law teams. Prior to Alexion, Mike was a corporate attorney at Wiggin and Dana LLP and Bingham McCutchen LLP (now Morgan Lewis).
OTHER THINGS WORTH KNOWING ABOUT ME:
My dream vacation is fishing in the fjords of Norway with my family.
My favorite book is Team of Rivals by Doris Kearns Goodwin.
My favorite city to visit is Pietrasanta, Italy (Portland, Maine, is a close second.)
Melissa has more than 15 years of toxicology experience, both academically and professionally. Prior to joining Rallybio, Melissa served as Executive Director and Head, Non-Clinical Toxicology and Attending Veterinarian at Alexion Pharmaceuticals. In addition to leading the development of the overall non-clinical toxicology strategy for all programs and serving as attending veterinarian, she oversaw the global toxicology team, designed, and monitored toxicology protocols, collaborated with stakeholder groups and provided strategic and operational direction for toxicology studies.
Melissa earned a B.S. in Animal Science from the University of Massachusetts, Amherst and a Doctor of Veterinary Medicine (DVM) from North Carolina State University College of Veterinary Medicine. She has been a certified Diplomate American Board of Toxicology (DABT) since 2011.
OTHER THINGS WORTH KNOWING ABOUT ME:
- My dream vacation: traveling through Europe and the UK to enjoy the food, culture, and architecture
- My favorite book/magazine is: Better and Complications, both by Atul Gawande
- When I’m not working, I’m…: hiking with my two dogs, a Labrador and a German Shepherd, or at the barn with my horses
Amanda is a molecular geneticist with 21 years of biopharmaceutical industry experience, specifically in business development and licensing transactions, venture capital, company building, and finance strategy. Most recently, she served as Managing Director of Venture Investments for Connecticut Innovations, investing in innovative biotherapeutics companies. Prior to that, she was a Partner at Baxalta Ventures. In addition to her role at Rallybio, she is Executive Chairman of Hoba Therapeutics and a Founding Partner at Eir Ventures.
Amanda earned her Ph.D. from Texas Tech University Health Sciences Center and was a postdoctoral fellow at Yale.
OTHER THINGS WORTH KNOWING ABOUT ME:
My dream vacation is Antarctica.
When I’m not working, I’m singing or hiking.
I grew up in Cornwall, England.
Lauren has more than a decade of experience in managing accounting processes and financial reporting. Before joining Rallybio, she served as Assistant Controller responsible for managing annual external financial audit procedures and quarterly reviews for Trevi Therapeutics. She previously served as Manager, Financial Planning and Analysis, at Spine Wave, Inc., and as an Accounting Manager at Kolltan Pharmaceuticals, Inc., where she helped build and maintain annual and long-range budgets, forecasts and business planning models.
Lauren earned a B.S. in accounting from Central Connecticut State University.
OTHER THINGS WORTH KNOWING ABOUT ME:
I cannot live without coffee.
My favorite city to visit is Kennebunkport, Maine.
Last concert I attended was Bruce Springsteen.
Laura brings over 30 years of combined experience in pharmaceutical research and clinical operations to Rallybio. Most recently, Laura was a Clinical Operations Leader at Cellectar Therapeutics working in rare hematology-oncology diseases. Prior to joining Cellectar, Laura spent 14 years at Melinta Therapeutics and Rib-X Pharmaceuticals in clinical operations advancing an antibiotic for acute skin infections and bacterial pneumonia. Early in her career, Laura conducted drug discovery research in microbiology for four years at Rib-X Pharmaceuticals and five years at Bristol Myers Squibb. She began her career as a Research Scientist at R.W. Johnson PRI.
Laura received a bachelor’s degree in biochemistry from North Carolina State University.
OTHER THINGS WORTH KNOWING ABOUT ME:
When I’m not working, I am exploring the mountains.
My favorite city to visit is Prague with its stunning and medieval Old Town.
My favorite animal is the clever Meerkat which despite its name is a mongoose.
Eric has about 15 years of experience in accounting. Prior to joining Rallybio, Eric was at Alexion for six years where he held several roles with increasing responsibility before his most recent role of Associate Director, Global Clinical Supply Planning. In this role, he forecasted drug supply needs for clinical trials and assisted with budgetary requirements for the clinical supply function of the company. Before joining Alexion, Eric served as a Senior Accountant and Senior Financial Analyst at Louis-Dreyfus Commodities. Eric began his career as an accountant at Hitachi Capital America.
Eric holds a Bachelor of Science in business management from Roger Williams University and a Bachelor of Science in accounting from Post University. He is a Certified Public Accountant.
OTHER THINGS WORTH KNOWING ABOUT ME:
When I’m not working, I am likely going out for a run. I have run distances from 5K’s all the way up to full marathons, but my preferred race distance is a half marathon!
I cannot live without coffee. It fuels me for the day and I find myself drinking multiple cups per day. Iced coffee is my preference and I love a good cold brew to kick off my morning.
My favorite sports team is The Atlanta Braves. I was fortunate enough to finally see my favorite team capture a World Series title in 2021! I am also a Miami Dolphins fan and I do not see any Super Bowl titles in their immediate future.
Jon is the Chief Financial Officer of Rallybio. He has more than 30 years of experience as a CFO for public and private life sciences companies and an investment banker. Most recently, he served as the CFO of Applied Genetic Technologies Corporation (AGTC), a publicly traded biotechnology gene therapy company focused on rare diseases, where he led all capital raising activities and was responsible for accounting and finance, human resources, investor relations, information technology and project management. Prior to AGTC, Jon was a Managing Director at Danforth Advisors, a private equity-backed firm, where he provided CFO services and strategic advice to public and private healthcare companies . Previously, he has served as CFO at firms including Histogenics, a publicly traded cell therapy company, Repligen, Xcellerex (acquired by GE Healthcare), and Altus Pharmaceuticals. Jon began his career in healthcare as an investment banker at Salomon Brothers / Salomon Smith Barney and SG Cowen.
Jon is a member of the board of directors of Salarius Pharmaceuticals and serves on the Audit and Nominating and Governance Committees.
Jon earned his Bachelor of Science in business administration and finance from Boston University and a master’s degree in finance from New York University’s Leonard N. Stern School of Business.
OTHER THINGS WORTH KNOWING ABOUT ME:
I cannot live without: A really good cup of coffee each morning
My greatest non-work accomplishment: Raising two terrific daughters (although my wife deserves much of the credit)
My favorite city to visit: Venice, Italy
Mark joins Rallybio with more than 20 years of industry experience in preclinical and clinical translational medicine.
Prior to joining Rallybio, Mark was the Executive Director of Bioanalytical and Biomarker Development at Alexion Pharmaceuticals, a subsidiary of AstraZeneca. Previously, Mark was the Director of Bioanalytical Sciences at Amgen Inc., where he provided support for preclinical drug development and bioanalytical and biomarker support to preclinical and clinical programs. Mark currently serves as the chair of the American Association of Pharmaceutical Scientists (AAPS) Bioanalytical Community and has led the pharmacokinetic assay working group under AAPS since 2014.
Mark earned his M.D. and master’s degree in immunology from Furth Medical University in Beijing, China.
OTHER THINGS WORTH KNOWING ABOUT ME:
My dream vacation is staying somewhere in nowhere, searching for the mysteries of nature.
My favorite book/magazine is the National Geographic Magazine.
My favorite sports team is the Los Angeles Lakers.
My greatest non-work accomplishment is writing prose. It’s more like a hobby, but I’ve received a lot of commendations.
Martin is a Co-Founder and Executive Chairman of Rallybio and has worked in pharmaceutical and biotech R&D for more than 30 years, holding leadership roles at companies including Pfizer, AstraZeneca, and Alexion. He is currently a member of the Board of Directors of Charles River Laboratories, and Novo Nordisk. He is also a Senior Advisor at New Leaf Ventures. Martin summarizes the three loves in his life as being family, work, and soccer, but not necessarily in that order.
Martin obtained a First-Class Honours Degree in microbiology from Heriot-Watt University and his Ph.D. in molecular genetics from the University of Edinburgh.
OTHER THINGS WORTH KNOWING ABOUT ME:
When I’m not working, I’m playing soccer, boating, ballroom dancing, training my GSD, and hanging with my grandchildren, Charlie and Sophie.
My favorite sports team is the Heart of Midlothian Football Club.
My greatest non-work accomplishment is still playing competitive soccer at 63.
Melissa has more than 7 years of experience in accounting. Prior to Rallybio, Melissa was a Senior Accountant at CliftonLarsonAllen where she managed accounts payable and accounts receivable functions as well as monthly close responsibilities for various entities. Previously, she served as a staff accountant at Enterprise Bank where she was responsible for financial reporting and analytics. Early in her career, she was in public accounting at Newburg & Company LLP (now Newburg CPA) where she held roles of increasing responsibility including Senior Accountant where she performed compilations, reviews and audits for various types of entities. Melissa began her career as a staff accountant at Melanson Health (now Melanson CPAs) where she helped perform governmental audits.
Melissa earned both her bachelor’s and master’s degrees in accounting from Plymouth State University.
OTHER THINGS WORTH KNOWING ABOUT ME:
When I’m not working, I’m golfing or hanging out with family and friends.
My favorite animal is my dog Arnie, a red tri Australian Shepard.
I grew up in Billerica, Massachusetts.
Kiran brings over 20 years of clinical research and development experience to Rallybio, including the design and execution of global clinical trials in severe and life-threatening rare disease indications. Prior to joining Rallybio, Kiran served as Vice President of Clinical Development at Gemini Therapeutics, where he led the company’s clinical development programs. Before this, he held clinical development leadership roles at Aeglea BioTherapeutics as Vice President of Rare Genetic Disease Clinical Development and at Alexion as Senior Medical Director and Global Research & Development Team Leader.
Kiran earned a Bachelor of Medicine and Bachelor of Surgery (M.B.B.S.) and M.D. from the University of Bombay, and a master’s in pharmaceutical medicine from Hibernia College. He is board certified by the American Board of Clinical Pharmacology.
OTHER THINGS WORTH KNOWING ABOUT ME:
My dream vacation is Geneva.
My favorite city to visit is Washington, DC.
My favorite charity is St. Jude Children’s Research Hospital.
Steve has more than 30 years of leadership experience in global healthcare development and a proven track record in the rare disease space. Prior to joining Rallybio, Steve served as Senior Vice President, Chief Development Officer at Alexion Pharmaceuticals, where he led the global development, registration, and approval of new drug candidates for rare diseases and contributed to the overall growth of the company. Previously, he was founding President of Astellas Pharma Global Development and spent 21 years in development at Pfizer.
Steve received his M.D. from the Icahn School of Medicine at Mount Sinai.
OTHER THINGS WORTH KNOWING ABOUT ME:
My dream vacation is two weeks anywhere with my family.
My favorite cities to visit are Seattle, WA, and Charlotte, NC (a tie.)
I grew up in Valley Stream, Long Island, NY.
Jackie has more than 35 years of diverse experience in global regulatory affairs, development, commercialization, and portfolio management from initial clinical investigation through registration. Prior to joining Rallybio, Jackie served as Vice President of Regulatory and Quality at Lyndra Therapeutics, with responsibilities for regulatory and quality strategies. Previously, she spent more than two decades in pharmaceutical sciences within Pfizer. During her time at Pfizer, she developed and led successful global CMC registration strategies for new small molecules, product enhancements, and combination products, and held regulatory leadership positions within the former Established Products Sterile Injectables organization.
She currently represents Rallybio on the Board of Directors for BIOCT (bioct.org) and the Soderstrom Scholars Fund, chairing the mentoring committee. In addition, Jackie is engaged with the BIO Rare Disease and Orphan Drug (RDOD) Specialty Committee, which provides a forum to discuss major advocacy issues and policies in relation to the development and marketing of orphan drug products.
Jackie received a B.A. in chemistry and in classical studies from Hamilton College.
OTHER THINGS WORTH KNOWING ABOUT ME:
I cannot live without chocolate and peanut butter.
My favorite sports team is the Buffalo Bills.
My favorite book is Mindset by Carol Dweck.
Doug has more than 20 years of R&D experience, both academically and professionally. He is a co-inventor of five clinical drug candidates for the treatment of rare diseases and one approved drug in the U.S., EU and Japan for the treatment of multiple complement-related disorders. Prior to joining Rallybio, Doug served as Executive Director, Global Program Team Leader, at Alexion Pharmaceuticals, where he led the cross-functional teams responsible for the development of drug-device combination products to enable patients with chronic disease to self-administer therapy subcutaneously.
Doug earned a B.S. in biochemistry and molecular biology from Pennsylvania State University, and a Ph.D. in neuroscience from Yale University.
OTHER THINGS WORTH KNOWING ABOUT ME:
When I’m not working, I’m hiking with my dog, Rosie. She is a cheerful and willing companion and rarely talks.
I cannot live without time alone outdoors. I’ve never had a good idea sitting at a desk.
My greatest non-work accomplishment is that I didn’t go to college after high school; I restored antique furniture professionally from age 19 to 27. Quitting my job to go to college as an adult was the most difficult thing I’ve ever done.
Kimberly has more than 15 years of experience in the biopharmaceutical industry. At Rallybio, she is responsible for managing external lab work and ensuring quality throughout various systems and procedures. Kimberly joined Rallybio from Alexion Pharmaceuticals, where she served as a compliance manager. In this role, Kimberly oversaw the integration of new molecules, implemented the company’s GxP system, managed compilations of metrics, and led internal audits. Additionally, Kimberly has worked at companies including the Protein Sciences Corporation, Monsanto and Premier Laboratory.
Kimberly earned her bachelor’s degree in biology at Eastern Connecticut State University and her master’s degree in regulatory affairs and quality assurance at Temple University.
OTHER THINGS WORTH KNOWING ABOUT ME:
My favorite magazine is the Scientific American.
I cannot live without cheese.
My greatest non-work accomplishment is surviving a year of homeschooling my young son during the quarantine of 2020-2021.
Michael has more than 23 years of biopharmaceutical experience, with expertise in project and portfolio management. Mike has been focused on driving R&D programs through all stages of development as well as improving operational performance of various R&D functions. Prior to joining Rallybio, Mike held leadership positions at Alexion Pharmaceuticals in R&D Strategy and Portfolio and Project Management, as well as in the Drug Safety organization. He also held positions of increasing responsibility in R&D portfolio and project management at Pfizer Inc. and while providing consulting services at BioTechLogic Inc. and Integrated Project Management Inc.
He earned a B.S. in industrial engineering from Iowa State University and an MBA from Lake Forest Graduate School of Management. Mike is a Certified Project Management Professional.
OTHER THINGS WORTH KNOWING ABOUT ME:
My favorite book is Devil in the White City.
My favorite animal is my dog, Wrigley.
My favorite sports teams are the Chicago Cubs, followed closely by da Bears.
Sam has 15 years of experience in both public and private accounting. Before joining Rallybio, she served as Controller for RJ Health Systems, where she oversaw accounting operations, developed annual budgets, and prepared financial forecasts, ensuring the fiscal welfare of the organization. Previously, she served as Director of Accounting at IsoPlexis Corporation and as a Senior Financial Analyst at HB Communications. In conjunction with regular accounting and finance functions, Sam has also been engaged in system implementations and integrations that have helped improve efficiencies and streamline workflows.
Samantha earned a B.S. in accounting from Stockton University.
OTHER THINGS WORTH KNOWING ABOUT ME:
When I’m not working, I’m spending my time outside (from hiking to gardening to chasing my twin boys around.)
I cannot live without music and laughter (and coffee.)
Last concert I attended was Flogging Molly.
Tara brings over 20 years of administrative experience to Rallybio. She began her career at Pfizer, where she held several positions during her 15-year tenure supporting the research and development teams. Most recently, she served as the Executive Assistant to Alexion Pharmaceutical’s Chief Quality Officer.
OTHER THINGS WORTH KNOWING ABOUT ME:
I cannot live without coffee.
When I’m not working, I’m sitting by my pool or gardening in the summer.
My greatest non-work accomplishment is raising my children – Anthony, Sophia and Gianni.
Steve is a Co-Founder and Chief Executive Officer of Rallybio. He has more than 25 years of experience, serving in R&D leadership roles with prominent global pharmaceutical and biotech firms. Steve was previously Head of Research at Alexion Pharmaceuticals, where he led a series of collaborations and external alliances, and expanded its research base beyond antibodies to include small molecules, RNA-based therapies and broader protein engineering capabilities. Prior to Alexion, Steve led research and development groups in Japan for Wyeth and Novartis Oncology, and held positions of increasing responsibility at Pfizer in the U.K., Japan and the U.S.
Steve received his medical training at the University of London’s St. Thomas’ Hospital Medical School, and then practiced clinical and academic medicine within the U.K.’s National Health Service and at the University of Manchester.
OTHER THINGS WORTH KNOWING ABOUT ME:
My dream vacation is diving in Truk Lagoon.
My favorite charity is the RNLI – Royal National Lifeboat Institution.
My greatest non-work accomplishment is 21 years of service in the U.K. Army Reserve (though it was sort of a job.)
Carrie has over 25 years of experience in life sciences in many different facets of the industry. She has a proven track record of leading and managing financial planning, business operations and strategic initiatives for both large and small companies. Prior to joining Rallybio, Carrie worked at Connecticut Innovations leading or supporting multiple early-stage venture deals in the bioscience portfolio and she was on the inaugural team launching the CTNext initiative. She also worked for Pfizer in progressive roles in both business and clinical operations. She is also active in the local bioscience community supporting multiple women-led initiatives.
Carrie holds a B.S. in Public Administration focused in Health Administration from the University of Arizona and an MBA focused on entrepreneurship from Northeastern University. She also has her Six Sigma Green Belt.
OTHER THINGS WORTH KNOWING ABOUT ME:
I cannot live without my morning coffee.
I grew up in Arizona.
When I’m not working, I’m spending time with my husband and my two kids.
Our Newest Team Members
Board of Directors
Helen is a retired senior executive with a 30-year career in the biotech, pharmaceutical, consulting, and banking industries. Most recently, Helen served as Chief Operating Officer of the Bill & Melinda Gates Medical Research Institute, a non-profit biotech. Over the course of her career, she held positions of increasing scope and responsibility in finance in the biotech and pharmaceutical industries, including Chief Financial Officer of Proteostasis Therapeutics, Chief Financial Officer of FORMA Therapeutics, Chief Financial Officer of Novartis Corporation US, and Chief Financial Officer Global Oncology, Novartis. Prior to Novartis, Helen held positions of increasing responsibility in strategy and finance at Pfizer Inc., including Vice President Finance Customer Business Unit and Commercial Operations and Vice President Finance, Pfizer Global Research and Development. Helen worked earlier in her career at PepsiCo Inc./YUM! Brands, Inc., McKinsey & Company, and Bank of America Corporation. She currently serves as a board member of Premier, Inc., Shattuck Labs Inc., and Field Trip Health Ltd. Helen previously served on the Board of Directors of Evaxion Biotech A/S and Proteostasis Therapeutics, Inc.
Helen earned a B.A. in economics from the University of Maryland, where she graduated summa cum laude, and an M.B.A. from the Darden Graduate School of Business at the University of Virginia.
Wendy is a board certified clinical and molecular geneticist with more than 20 years of experience in human genetic research. Wendy is currently the Kennedy Family Professor of Pediatrics in Medicine and Director of Clinical Genetics at Columbia University. She is also the Director of Precision Medicine Resource in the Irving Institute and the National Organization for Rare Disorders Center of Excellence at Columbia University. She has authored over 600 peer reviewed papers and 75 reviews and chapters in medical texts. She was the recipient of the Medical Achievement Award from Bonei Olam, the Dade County Hall of Fame, the NY Academy of Medicine Medal for Distinguished Contributions in Biomedical Science, the Rare Impact Award from the National Organization for Rare Disorders and is a member of the National Academy of Medicine. Wendy is a member of the Scientific Advisory Board for Sage Bionetworks, Taysha, Helix, and Regeneron Genetics Center.
Wendy earned a B.A. in Biochemistry and Economics from Cornell University, a M.D. from Cornell University Medical College, and a Ph.D. in Genetics from The Rockefeller University.
Rob is a Managing Partner at Pivotal bioVenture Partners LLC, where he focuses on drug discovery and development investments. He has a long track record of working successfully with entrepreneurs to progress novel, important medicines through development and onto the market. Prior to Pivotal, Rob served as a Principal at Bay City Capital LLC. He previously held business development and investment roles at DuPont Pharmaceuticals and Ag-West Biotech LLC. Rob started his career as a pharmacist after completing his post-doctoral work at Harvard Medical School. Rob currently serves as a board member of Vaxcyte, Inc. and Inozyme Pharma, Inc., and on the boards of a number of private life sciences companies.
Rob earned a B.Sc. in pharmacy and a Ph.D. in pharmacology from the University of Saskatchewan and an MBA from the University of Chicago Booth School of Business.
Ron is a Managing Director at New Leaf Venture Partners, where he focuses on early- to late-stage investments in biopharmaceuticals. He was one of the founders of New Leaf in 2005, and today has over two decades of experience investing in and building companies focused on developing novel medicines that address important unmet medical needs. Prior to New Leaf, Ron was a partner at the Sprout Group, a venture capital firm, and was a consultant with Coopers & Lybrand Consulting and The Health Care Group, Inc. He previously held various sales and marketing positions at Johnson & Johnson and SmithKline Beecham Pharmaceuticals PLC. Ron currently serves on the board of directors of Harpoon Therapeutics, Inc. and Iterum Therapeutics, Ltd. Ron is also on the boards of a number of private pharmaceutical companies. He previously served on the board of directors of Neuronetics, Inc., a medical device company.
Ron earned a B.S. from Cornell University and an MBA from the Wharton School of the University of Pennsylvania.
Lucian is a Managing Director with TPG Growth, where he focuses on healthcare investing. Prior to TPG, Lucian served as the head of the Qualcomm Life Fund, a venture fund focused on investing in digital health technologies. He was also a general partner at dRx Capital, a joint venture investment company launched by Novartis and Qualcomm. Previously, Lucian worked at McKinsey & Company in the North American healthcare practice, advising on clinical- and business-model transformation for large hospital systems. Lucian is a board-certified internal medicine doctor who trained at Columbia University Medical Center in New York prior to joining McKinsey & Company.
Lucian earned both his bachelor’s degree in economics and an M.D. from Tufts University.
Hui is a seasoned biopharma executive with 25 years of experience in business development, finance, and strategy. He is currently the Executive Vice President, Chief Business Officer and Head of US at Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company engaged in developing multispecific antibody therapeutics. Prior to Merus, Hui was the Global Head of Business Development & Licensing at Novartis Oncology. Prior to this, he served as Global Head of Business Development and Licensing for Novartis Vaccines & Diagnostics. Hui began his pharma career in business development at Pfizer where he held roles of increasing responsibility. Prior to Pfizer, he worked in investment banking at Citigroup and Goldman Sachs.
Hui earned a B.S. in biology from Peking University in Beijing, China and both an M.B.A. in finance and Ph.D. in molecular biology from the University of Michigan.
Martin is a Co-Founder and Executive Chairman of Rallybio and has worked in pharmaceutical and biotech R&D for more than 30 years, holding leadership roles at companies including Pfizer, AstraZeneca, and Alexion. He is currently a member of the Board of Directors of Charles River Laboratories, and Novo Nordisk. He is also a Senior Advisor at New Leaf Ventures. Martin summarizes the three loves in his life as being family, work, and soccer, but not necessarily in that order.
Martin obtained a First-Class Honours Degree in microbiology from Heriot-Watt University and his Ph.D. in molecular genetics from the University of Edinburgh.
Christine is a marketing and commercial executive with 20 years of experience in emerging biopharmaceutical companies. As Principal at Chatiemac Consulting, LLC, she provides strategic and commercial planning guidance to biotechnology companies developing medications for rare diseases. Christine also currently serves as Board Chair and senior advisor to the President and CEO at The CM Group, an integrated healthcare agency focused on providing scientific and commercialization strategies and services to life sciences companies. Previously, Christine was at Hyperion Therapeutics, Inc., where she held roles of increasing responsibility in marketing and business development, including Chief Commercial Officer, until Hyperion’s acquisition by Horizon Pharma. Prior to Hyperion, Christine held marketing roles at Cotherix, Inc., until its acquisition by Actelion. Early in her career, she was a Product Manager at Genesoft Pharmaceuticals until its acquisition by Oscient Pharmaceuticals.
Christine earned both a B.A. with honors in public policy and an M.B.A. from Stanford University.
Kush is a Managing Partner at 5AM Ventures. He also serves as Co-Chief Executive Officer and as member of the Board of Directors of 5:01 Acquisition Corp. Kush serves as a board member of Akouos, Inc., Entrada Therapeutics, Inc., Ensoma Inc., Homology Medicines, Inc., Vor Biopharma Inc., and Syngene International Limited, and previously served on the board of directors of Arvinas, Inc., Audentes Therapeutics, Inc., and scPharmaceuticals, Inc. He also serves on the Advisory Boards of Harvard Medical School, Penn Medicine, Princeton University’s Department of Molecular Biology, and the Grace Science Foundation. Kush is a Fellow of the Society of Kauffman Fellows. Prior to 5AM, Kush was at Harvard Medical School, where he was an NIH-sponsored MD/PhD Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program.
Kush earned a B.A. in molecular biology and medieval studies from Princeton University, a Ph.D. in experimental pathology from Harvard University, and an M.D. from Harvard Medical School.
Paula currently serves as lead independent director of the Board. Paula has more than 30 years of rare disease biopharma industry experience in strategic and operational leadership areas including drug development, global commercialization, manufacturing, new company formation, and company building. In addition to a strong focus on rare disease, her career spans a broad range of therapeutic areas including cardiovascular and metabolism, neurology, infectious disease, renal, transplant, and oncology. Paula previously served as founding CEO and member of the Board of Directors of Akcea Therapeutics. Prior to Akcea, she was Senior Vice President and General Manager of Cardiometabolic and Rare Disease Businesses and Strategic Alliances at Moderna, Inc. where she led key strategic alliances and built preclinical programs. Before Moderna, Paula spent more than 20 years at Genzyme Corporation where she held positions of increasing responsibility including Vice President and General Manager, Cardiovascular, Rare Diseases. She currently serves as Executive Chairman of Ensoma and as a member of the Board of Directors of uniQure. Paula also serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University.
Paula earned both a B.S. in chemical and biochemical engineering and an M.S. in chemical and biochemical engineering from Tufts University, and holds an executive management certificate from the Darden Graduate School of Business at the University of Virginia.
Steve is a Co-Founder and Chief Executive Officer of Rallybio. He has more than 25 years of experience, serving in R&D leadership roles with prominent global pharmaceutical and biotech firms. Steve was previously Head of Research at Alexion Pharmaceuticals, where he led a series of collaborations and external alliances, and expanded its research base beyond antibodies to include small molecules, RNA-based therapies and broader protein engineering capabilities. Prior to Alexion, Steve led research and development groups in Japan for Wyeth and Novartis Oncology, and held positions of increasing responsibility at Pfizer in the U.K., Japan and the U.S.
Steve received his medical training at the University of London’s St. Thomas’ Hospital Medical School, and then practiced clinical and academic medicine within the U.K.’s National Health Service and at the University of Manchester.
Commitment to Patients
We’re not here to make an incremental difference.
ANYTHING IS POSSIBLE WHEN WE RALLY
When we RallyTogether, we can uplift each other, our patients, our community, and the world around us.
At Rallybio, our goal is to meaningfully improve the lives of patients suffering from severe and rare diseases by harnessing the decades of knowledge and experience of our team to deliver transformative therapies.
Internally, we foster our inclusive culture and values to cultivate a great place to work, where our employees can be candid, courageous, and tenacious in their pursuits, as we work every day to deliver on our mission.
While Rallybio might be a small company, we believe we can make a big impact. We believe that proactively launching our ESG program (and our Impact Report) will help strengthen our foundation to ensure our company to ensure that we can deliver long-term value for our stakeholders and lasting impact for our patients.
Learn more and read our inaugural Impact Report.